Status and phase
Conditions
Treatments
About
To date no targeted agents are available to treat TNBC. Therefore chemotherapy is the only treatment option. TNBC often has a high amount of tumour infiltrating lymphocytes. Stimulating the immune cells of TNBC might therefore be an option for these patients to increase the pathological complete response. pCR is highly correlated with outcome in TNBC.
Therefore the addition of a checkpoint inhibitor in addition to chemotherapy might be an additional option for these patients.
Full description
To date no targeted agents are available to treat TNBC. Therefore chemotherapy is the only treatment option. TNBC often has a high amount of tumour infiltrating lymphocytes. Stimulating the immune cells of TNBC might therefore be an option for these patients to increase the pathological complete response. pCR is highly correlated with outcome in TNBC.
Therefore the addition of a checkpoint inhibitor in addition to chemotherapy might be an additional option for these patients.
The primary objective therefore is to compare the pathological complete response (pCR= ypT0 ypN0) rates of neoadjuvant treatment of sequential, nab-Paclitaxel followed by EC +/- the PD-L1 antibody MEDI4736 in patients with early triple negative breast cancer.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
In patients with multifocal or multicentric breast cancer, the largest lesion should be measured.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
174 participants in 5 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal